Study #2020-0776
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Futibatinib, Pembrolizumab
Description
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Study phase:
Phase II
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-961-3045
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.